New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 10, 2014
09:31 EDTVRX, NSRGYValeant completes filler, toxin asset sale to Galderma
Valeant Pharmaceuticals (VRX) announced it has completed the sale to Galderma of all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant for $1.4B in cash, pursuant to the previously announced agreement with Nestle (NSRGY) which recently completed its acquisition of Galderma.
News For VRX;NSRGY From The Last 14 Days
Check below for free stories on VRX;NSRGY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
August 22, 2014
09:33 EDTVRXValeant to request today special meeting of Allergan holders, CNBC reports
Valeant (VRX) will deliver today a request of 30%-plus of Allergan (AGN) shareholders for a special meeting, CNBC's David Faber reports, citing sources.
06:49 EDTVRXJudge rejects Allergan inquiry to quicken insider trading case, Reuters says
Subscribe for More Information
06:45 EDTVRXJudge refuses to prevent special Allergan shareholder meeting, NY Times says
Subscribe for More Information
August 21, 2014
09:42 EDTVRXValeant to sell Precision's assets related to two acne treatments
Subscribe for More Information
August 20, 2014
17:59 EDTVRXAllergan talks with Salix in defense tactic said to be dormant, Bloomberg says
Subscribe for More Information
17:35 EDTVRXAllergan said to explore options outside of Salix acquisition, Bloomberg says
Subscribe for More Information
10:53 EDTVRXAnalysts say Salix takeover would boost Allergan
Subscribe for More Information
09:46 EDTVRXAllergan merger deal not imminent, CNBC's Faber reports
An acquisition by Allergan (AGN) is not imminent, CNBC's David Faber reports. Salix (SLXP) and Jazz Pharmaceuticals (JAZZ) are said to be potential targets of the company, Faber adds. Valeant (VRX) could announce over the next few days that it has enough votes to call for a special meeting, the reported said.
07:07 EDTVRXSome Valeant shareholders express uncertainty over Allergan deal, Reuters says
Subscribe for More Information
August 19, 2014
17:14 EDTVRXOn The Fly: Closing Wrap
Subscribe for More Information
16:52 EDTVRXAllergan all-cash deal would reduce hostile bid chances, says BMO Capital
Subscribe for More Information
13:13 EDTVRXAllergan approached Salix, one other about takeover, WSJ reports
Subscribe for More Information
August 18, 2014
15:59 EDTVRXAllergan CFO change may suggest strategic deal near, says BMO Capital
BMO Capital believes former Allergan (AGN) CFO Jeff Edwards would not be leaving if a change of control of the company, such as a takeover by Valeant (VRX), were in the future. Rather, BMO thinks Edwards' decision to leave could be a sign that a strategic transaction marking a new chapter in Allergan's growth may be nearing. The firm thinks Allergan is in capable hands with new CFO Jim Hindman and it keeps an Outperform rating on the stock with a $230 price target.
August 15, 2014
17:03 EDTVRXValeant extends offer to acquire Allergan
Valeant Pharmaceuticals (VRX) announced that it has extended the expiration of its exchange offer to acquire all of the outstanding shares of Allergan (AGN) to December 31. The exchange offer was previously scheduled to expire August 15. All other terms and conditions of the exchange offer remain unchanged.
14:14 EDTVRXValeant being probed by IRS after Biovail deal, FT says
Subscribe for More Information
09:45 EDTVRXEvent-driven funds, Pershing own over 20% of Allergan, CNBC reports
Event-driven hedge funds and Pershing Square owned over 20% of Allergan as of June 30, CNBC's David Faber reports. Valeant (VRX) and Pershing are seen as getting the over 30% to call a special meeting, Faber adds.
August 14, 2014
17:41 EDTVRXPoint72 Asset Management gives quarterly update on stakes
Subscribe for More Information
14:28 EDTVRXAckman says Pershing, Valeant took no tender steps before buying Allergan shares
Bill Ackman made the statement to CNBC's Scott Wapner regarding his fund and Valeant's (VRX) pursuit of Allergan (AGN). Note that the Wall Street Journal reported earlier that the SEC is investigating Valeant and Pershing's pursuit of Allergan.
13:48 EDTVRXValeant, Pershing joint bid for Allergan being probed by SEC, WSJ says
Subscribe for More Information
13:22 EDTVRXValeant, Pershing joint bid for Allergan being probed by SEC, DJ says
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use